Mumbai: Health equipment manufacturer Opto Circuits has received approval from the US Food and Drug Administration (US FDA) to market two of its products in the country.
Mediaid Inc, the wholly-owned subsidiary of Opto Circuits (India) Ltd, has received approval from the US FDA for marketing its vital sign monitoring products in the US, the company said in a filing to the Bombay Stock Exchange.
“The model 900 and model 960 vital sign monitors are the first Opto bed side monitors to receive the approval from the US FDA,” the filing said.
“The devices are used to monitor blood-oxygen, blood pressure and temperature for a complete and quick assessment of vital signs,” it added.
In February, Opto Circuits had entered into a definitive agreement with Criticare Systems Inc to buy the US-based firm for about $70 million. Criticare Systems manufactures vital sign monitors, anesthesia monitors and pulse oximeters.
Shares of Opto Circuits were trading at Rs352.50, down 2.27% in afternoon trade on the BSE.